CLOs on the Move

Connectyx

www.connectyx.com

 
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a trading symbol (CURB) with the Financial Industry Regulatory Authority, Inc., which should take effect in the first quarter of 2021. Connectyx is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.connectyx.com
  • 1825 NorthWest Corporate Boulevard Suite 110
    Boca Raton, FL USA 33431
  • Phone: 800.526.8006

Executives

Name Title Contact Details
Richard Garr
Chief Executive Officer and General Counsel Profile

Similar Companies

Rainin Instrument

Rainin Instrument is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.